home / stock / lobe:cc / lobe:cc news

LOBE:CC News and Press, Lobe Sciences Ltd. From 11/08/22

Stock Information
Company Name: Lobe Sciences Ltd.
Stock Symbol: LOBE:CC
Market: CNQC
Website: lobesciences.com
Menu
LOBE:CC LOBE:CC Quote LOBE:CC Short LOBE:CC News LOBE:CC Articles LOBE:CC Message Board
Get LOBE:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
LOBE:CC - Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") today announced that Philip Young, CEO and Executive Director, will present at the MONEYSHOW VIRTUAL EXPO, November 10 th at 10:40AM EDT. The present...
LOBE:CC - Trip to Treatment: Lobe Sciences CEO Touts Targeted Low Dosing for Better Patient Outcomes

Trip to Treatment: Lobe Sciences CEO Touts Targeted Low-dosing for Better Patient Outcomes youtu.be - YouTube Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) is taking a different approach to psychedelic treatment by using low-dose, sub-psychedelic stimulation...

LOBE:CC - Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Appointment of Philip J. Young, CEO, as Board Chairman Vancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived m...

LOBE:CC - Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced...
LOBE:CC - Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings

Resignation of Board Chairman, Jonathan Gilbert and Shares for Debt Transactions Vancouver, British Columbia--(Newsfile Corp. - October 3, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and develop...

LOBE:CC - Lobe Sciences Announces Incorporation of Australian Subsidiary

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today ...

LOBE:CC - Lobe Sciences Announces Closing of Private Placement

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announ...
LOBE:CC - Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announc...

LOBE:CC - Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced...

LOBE:CC - Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced...
Previous 10 Next 10